Drug Trial Radar · NCT01696123
Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine
Last checked: Nov 19, 2026Latest source record: Sep 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Jan 2011
Primary completion
Jan 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Shahid Beheshti University of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 28, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Current therapeutic approaches for the treatment of neurodegenerative diseases like Alzheimer disease (AD) offer limited and often transient symptomatic benefits to patients but do not mitigate the insidious loss of neuronal cells. In this trial the investigators will evaluate Efficacy and Tolerability of MLC601 as a neuroprotective in Patients with Mild to Moderate Alzheimer Disease who Were Unable to Tolerate or Failed to Benefit from Treatment with Rivastigmine.
Conditions
- Alzheimer Disease
Interventions
MLC601Drug
It was described
Primary outcomes
What the sponsor says the trial is designed to measure.
- changes in the Mini-Mental State Examination (MMSE) relative to baseline measurementsTime frame: every 4 weeks up to 18 months
- changes in the cognitive subscale of the AD Assessment Scale (ADAS-cog) relative to baseline measurementsTime frame: every 4 weeks up to 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Loghman Hospital
Tehran, Tehran Province, Iran
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.